" Evaluation of Erythropoietin Therapy in Patients With End-Stage Kidney Disease on Regular Hemodialysis: Hemoglobin Outcomes, and Metabolic Syndrome as a Risk Factor for Erythropoietin Resistance "

ConditionErythropoietin Resistant Anemia (EPO Resistant Anemia)

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorFayoum University

About this trial

The primary aim of this study is to investigate the association between metabolic syndrome and erythropoietin resistance in patients with End-Stage Kidney Disease (ESKD).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patients (and replacements) will be randomly selected by a raffle.

All participants should be 18 years of age or older and agree to participate in the study after due clarification.

Patients with end stage kidney disease (ESKD) on regular hemodialysis for more than 3 months.

Disqualifiers

- Patients with neoplasm, severe cardiovascular, cerebrovascular and liver diseases.

Females with polycystic ovarian syndrome, those on hormonal replacement therapy and pregnant women.

Patients with infection or autoimmune diseases.

Trial population

The patients who will be enrolled in this study are receiving recombinant human erythropoietin therapy with epoetin alfa (αEPO), used to control anemia at our reference hospital.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Erythropoietin
Drug
EPO resistance

Treatment groups

66 Participants

are divided into 2 treatment groups

Group A: group 11 intervention

Group B: group 21 intervention

Trial outcomes

Primary outcomes

Hemoglobin in blood

Time frame

6 month

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fayoum University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: